HC Wainwright Has Positive Estimate for MBRX FY2025 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for Moleculin Biotech in a note issued to investors on Monday, March 24th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($1.65) for the year, up from their previous estimate of ($3.31). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

A number of other equities research analysts have also recently issued reports on the stock. Maxim Group upgraded shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Tuesday. StockNews.com raised Moleculin Biotech to a “sell” rating in a research report on Wednesday.

Moleculin Biotech Price Performance

MBRX stock opened at $1.07 on Thursday. The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.99. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $6.23.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.